Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Kim Christiansen discusses her experiences managing limited mobility and chronic pain from a partial spinal cord injury and Dr Natalie Hoff describes good physical therapy care for patients with chronic migraine headaches.
Differentiating between best palliative care options and the curative and palliative potential of surgery is key to developing dual intentional clarity.
AMA J Ethics. 2021;23(10):E766-771. doi:
10.1001/amajethics.2021.766.
Editorial fellow Dr Ariel Wampler describes what few know about material and device regulation, and Dr Adriane Fugh-Berman explains why we should ask more questions about device representatives’ intraoperative roles during implantations.
Jeffrey Bedard joins Ethics Talk to discuss his article: "What Should Patients Be Told About Device Representatives’ Roles at the Point of Surgical Care?"
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Expedited partner therapy is an ethical and effective treatment for sexually transmitted infection, provided patients are reliable messengers to partners.
AMA J Ethics. 2016;18(3):215-228. doi:
10.1001/journalofethics.2016.18.3.ecas3-1603.